Skip to main content
. 2022 Jul 22;41(1):107–116. doi: 10.1200/JCO.22.00430

FIG 2.

FIG 2.

Generalized additive model with Cox proportional hazard ratios of PFS benefit in veliparib-throughout arm 3 versus placebo arm 1 according to KELIM in (A) patients with BRCA mutation, (B) BRCA wild-type HRD cancer, and (C) HRP cancer. The cutoff at 0.024 was the KELIM median value. HRD, homologous recombination deficiency; HRP, homologous recombination proficiency; KELIM, elimination rate constant K; PFS, progression-free survival.